Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/15/2025

Nebivolol and Weight Neutrality

Key Evidence Supporting Weight Neutrality

  • The American Heart Association and American College of Cardiology recommend avoiding traditional beta-blockers as first-line treatment in overweight or obese patients due to weight gain concerns, and instead suggest selecting nebivolol or carvedilol when beta-blockers are medically required 1, 2, 3
  • The Gastroenterology guidelines state that selective beta-blockers with a vasodilating component, such as nebivolol, have less potential for weight gain and minimally affect lipid and glucose metabolism 1, 2

Clinical Recommendation Algorithm

  • For patients with weight concerns requiring antihypertensive therapy, the American College of Cardiology recommends first-line options such as ACE inhibitors, ARBs, or calcium channel blockers, which are weight-neutral 3, 4
  • If a beta-blocker is required, the American College of Cardiology recommends choosing nebivolol or carvedilol over traditional beta-blockers such as atenolol, metoprolol, or propranolol 1, 2, 3

REFERENCES

3

Management of Hypertension in Obese Patients [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Blood Pressure Management for Weight-Concerned Patients [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026